GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Niki BioSolutions, NIKI · USD

US listing · 🇺🇸 United States

Compare

1.75

+10.76%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Niki BioSolutions, — daily NIKI Delayed
Market value
$128,625
Last close × shares
Volume
38.3k
Shares, 9 Nov 2026

About Niki BioSolutions,

Its shares trade under the ticker NIKI. It has been listed since 17 July 2026. In the fiscal year to 31 December 2025, it reported a net loss of $1.4m. At that date it held total assets of $18.7m and shareholders' equity of $23.2m.

Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.

Figures and description from our data supplier, not checked against the company's own report.

More about Niki BioSolutions, →

Latest on Niki BioSolutions,

Our reporting

We have not reported on Niki BioSolutions, yet.

Other United States listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Niki BioSolutions,'s ticker?

Niki BioSolutions, trades as NIKI on its US listing, under ISIN US6539421023.

What was Niki BioSolutions,'s last closing price?

1.75 on 9 Nov 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.